Ana Gómez Fernández
analystFemale0.0Global Dominance: 0.00%
Ana Gómez Fernández is an analyst with Renta 4, specializing in the pharmaceutical industry. She provides insights into the clinical developments of weight loss medications and emphasizes caution regarding emerging therapies, noting the need for thorough evaluation of their efficacy and safety.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Ana Gómez Fernández from Renta 4 cautions about the early development phases of obesity treatments.
¿Quién será el nuevo Ozempic? El mercado acelera la búsqueda de la siguiente revolución en la lucha contra la obesidad | Mercados FinancierosEl País·
Spain· 2025-02-10
Spain· 2025-02-10
